Aviptadil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Aviptadil Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Aviptadil can convert its Synthetic peptide profile and VIPR1 x VIPR2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Aviptadil (query alias: Aviptadil) |
|---|---|
| Modality / target | Synthetic peptide; VIPR1 x VIPR2; VIPR1 agonists, VIPR2 agonists |
| Highest global status | Approved |
| Originator | United Therapeutics Corp. |
| Active developers | RELIEF THERAPEUTICS Holding SA, NRX Pharmaceuticals, Inc., Kantonsspital Baselland |
The MCP disease footprint includes COVID-19, Pneumonia, Respiratory Distress Syndrome, Adult. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06729606 | Phase 3 | Completed | 471 | Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90 |
| CTRI/2024/10/075314 | Phase 3 | Open to Recruitment | 240 | Not disclosed |
| NCT05137795 | Phase 3 | Withdrawn | Not disclosed | Progression to Respiratory Failure |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Contemporary patterns of treatment and outcomes in germ-cell tumors across a provincial cancer system: British Columbia Germ Cell Tumor Clinical Database.
Not Applicable; n=2366; evaluation: Positive. Reported fields: OS(from diagnosis) = 96.5 % ( 92.8 - 98.7); -
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With Acute Respiratory Distress Syndrome Associated With COVID-19 (Trial H1: Aviptadil)
Phase 3; n=471; evaluation: not stated. Reported fields: Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90: Odds Ratio (OR) = 1.11(95% CI, 0.80 - 1.55), P-Value = 0.54; Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90: Odds Ratio (OR) = 1.11(95% CI, 0.80 - 1.55), P-Value = 0.54; Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90: Odds Ratio (OR) = 1.11(95% CI, 0.80 - 1.55), P-Value = 0.54
ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure
Phase 2/3; n=203; evaluation: not stated. Reported fields: Resolution of Respiratory Failure (Alive and Free of Respiratory Failure) = 33 Participants ; Resolution of Respiratory Failure (Alive and Free of Respiratory Failure) = 72 Participants ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Aviptadil addresses COVID-19, Pneumonia, Respiratory Distress Syndrome, Adult. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-11-14 | Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements | Not disclosed | US$30.0M stated total |
| 2021-08-04 | NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions | Phase 3 | Financial terms not disclosed |
| 2021-03-09 | NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
